A Treatment Option for Patients with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Room: 200/201/202
Learn more about a treatment option that may help appropriate patients with uncontrolled moderate-to-severe atopic dermatitis.
Sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
